Myelofibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Abbvie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, Ns Pharma, Galecto Biotech, Actuate Therapeutics, Merck, Menarini Group, Telios Pharma,

Myelofibrosis therapies, such as JAKAFI/JAKAVI (ruxolitinib), INREBIC (fedratinib), XPOVIO (selinexor), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), and others, are expected to boost the Myelofibrosis Market in the upcoming years.

DelveInsight has launched a new report on "Myelofibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Myelofibrosis market report @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Myelofibrosis Market Report:

In 2024, the myelofibrosis market size across the 7 major markets (7MM) was estimated at approximately USD 2.2 billion, with projections indicating continued growth through the forecast period (2024-2034). The United States accounted for the largest share, generating nearly USD 1.7 billion, significantly surpassing the market sizes of EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
In June 2025, the FDA granted Fast Track status to nuvisertib, a PIM1 kinase inhibitor being developed by Sumitomo Pharma, for intermediate to high-risk myelofibrosis .
Within the therapeutic landscape, JAKAFI/JAKAVI (ruxolitinib) led the market in 2024 with a value of around USD 1.5 billion, making it the dominant therapy for myelofibrosis. JAK inhibitors have become the cornerstone of treatment, offering substantial benefits in spleen volume reduction, symptom control, and quality of life, especially in patients with advanced disease.
All currently approved JAK inhibitors target JAK2, although their molecular profiles vary:
JAKAFI: a dual JAK1/JAK2 inhibitor

INREBIC: selectively inhibits JAK2, spares JAK1, but also acts on FLT3

VONJO: targets JAK2, while sparing JAK1 and inhibiting FLT3, IRAK, and ACVR1

OJJAARA: a JAK1/JAK2 and ACVR1 inhibitor, mainly indicated for myelofibrosis with anemia

These differing mechanisms contribute to distinct clinical outcomes and tolerability profiles across patient subgroups.
JAKAFI remains in high demand and is expected to maintain its leadership position as the standard of care. According to Incyte, myelofibrosis will continue to represent the largest share of JAKAFI's use until its share among polycythemia vera patients expands.
However, market growth faces a challenge from patent expirations-with JAKAFI's patents set to expire in 2027 for Novartis and 2028 for Incyte, opening the door for generic competition. To mitigate this, Incyte is actively exploring combination therapies with novel agents to extend JAKAFI's relevance and clinical utility.
Emerging therapies are exploring non-JAK pathways, offering promising alternatives, including:
Imetelstat (a telomerase inhibitor)

Navtemadlin (an MDM2 protein inhibitor)

Pelabresib (a BET inhibitor)

These investigational agents may address unmet needs, especially for patients with resistance, intolerance, or suboptimal response to JAK inhibitors.
The evolving myelofibrosis treatment landscape presents strong opportunities for innovation-particularly in developing effective options for lower-risk patients, advancing first-line regimens for intermediate-to-high-risk individuals, and introducing therapies to manage cytopenias, a significant unmet clinical need.
In 2024, the total number of myelofibrosis prevalent cases across the 7 major markets (7MM) was estimated to be around 55,900, with this number expected to grow over the forecast period (2020-2034).
Within the EU4 and the UK, Germany reported the highest number of diagnosed prevalent myelofibrosis cases, followed by Spain, while the UK recorded the lowest number of cases in that year.
Key Myelofibrosis companies such as Abbvie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, Ns Pharma, Galecto Biotech, Actuate Therapeutics, Merck, Menarini Group, Telios Pharma, Disc Medicine, Syntara, Sumitomo Pharma, Incyte, and others are evaluating new drugs for Myelofibrosis to improve the treatment landscape.
Promising Myelofibrosis therapies include JAKAFI/JAKAVI (ruxolitinib), INREBIC (fedratinib), XPOVIO (selinexor), RYTELO (imetelstat), REBLOZYL (luspatercept/ACE-536), and others.

Myelofibrosis Overview

Myelofibrosis is a rare form of blood cancer marked by the accumulation of scar tissue-known as fibrosis-within the bone marrow. This scarring disrupts the marrow's ability to produce adequate healthy blood cells. It falls under a broader category of blood cancers called myeloproliferative neoplasms (MPNs), in which blood-forming cells grow and function abnormally.
When myelofibrosis arises on its own without a preceding condition, it is referred to as primary myelofibrosis. However, it can also develop as a progression of other MPNs, such as polycythemia vera or essential thrombocythemia. In such cases, it is classified as secondary myelofibrosis, sometimes specifically called post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
The disease typically progresses slowly and may initially be asymptomatic, often detected incidentally through routine blood tests. As fibrosis advances, the bone marrow's capacity to produce normal blood cells diminishes, leading to many of the condition's clinical manifestations.
Several gene mutations have been associated with myelofibrosis, most notably JAK2, with CALR and MPL mutations also observed in some patients. However, a subset of individuals may not present with any known mutations.
Common clinical signs and symptoms include:
Anemia

Enlargement of the liver and spleen (hepatosplenomegaly)

Systemic symptoms such as fatigue, night sweats, low-grade fever, and unintended weight loss (cachexia)

Bone pain, splenic infarction, itching (pruritus), extramedullary hematopoiesis outside the liver and spleen, thrombosis, and bleeding complications

These features reflect the complex and multi-systemic nature of the disease and underscore the need for ongoing monitoring and targeted management.

Myelofibrosis Market Outlook

Myelofibrosis has limited therapeutic options, with allogeneic hematopoietic cell transplantation remaining the only potentially curative treatment-though it is accessible to only a small subset of patients. For a significant period, JAKAFI (ruxolitinib) was the sole approved therapy for intermediate- to high-risk myelofibrosis, until INREBIC (fedratinib) received FDA approval in August 2019. Studies show that both ruxolitinib and fedratinib offer comparable efficacy, though their safety profiles differ. Notably, fedratinib carries a black box warning due to the risk of encephalopathy.

In February 2022, the FDA approved VONJO (pacritinib) for patients with intermediate or high-risk primary or secondary myelofibrosis and severely low platelet counts (

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.